Abbisko Cayman Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The company is headquartered in Shanghai, Shanghai and currently employs 226 full-time employees. The company went IPO on 2021-10-13. The firm is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The firm owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).
02256.HK stock price ended at $14.27 on 금요일, after dropping 3.12%
On the latest trading day Jan 16, 2026, the stock price of 02256.HK fell by 3.12%, dropping from $14.26 to $14.27. During the session, the stock saw a volatility of 3.02%, with prices oscillating between a daily low of $14.26 and a high of $14.69. On the latest trading day, the trading volume for 02256.HK decreased by 1.0M shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 199.0K shares were traded, with a market value of approximately $9.4B.
02256.HK 기술적 시그널
기술적 시그널 요약
구매 신호 3
중립 신호 1
매도 신호 3
Strong Sell
Sell
Neutral
Buy
Strong Buy
02256.HK은 현재 3개의 매수 신호와 3개의 매도 신호를 보이고 있습니다. 이 주식은 12:00 AM 이후로 하락 추세 상태에 있으며, 이 기간 동안 총 가격 변동률은 -3.12%입니다. 전반적으로 기술적 지표들은 중기적으로 Neutral 전망을 나타내고 있습니다.
02256.HK에 대한 강세/약세 신호
이동평균, RSI, MACD, 거래량 등 핵심 지표를 분석하여 02256.HK 의 강세/약세 시그널을 생성합니다. 이 인사이트를 활용해 더 현명한 투자 결정을 내리세요.